AI was priced as software.
Buyers were pricing it as
recovered revenue.
Willingness-to-pay validated at roughly thirty times the company’s initial pricing assumptions, anchored to a $90M ARR five-year path.
A market-dominant clinical guideline company
with a working AI product and no commercial model.
Thirty-five years in operation. Three thousand clinical guidelines. Roughly seventy percent U.S. payer market penetration. An AI-powered appeal-letter generator embedded directly in Epic EHR workflows, helping hospital systems fight insurance denials for medical necessity in minutes instead of hours.
The product worked. The commercial strategy did not exist. No validated pricing. No quantified willingness to pay. No market sizing beyond internal estimates. No structured launch plan. The tool was being offered as a zero-dollar pilot with no framework for converting to paid contracts, and AI governance reviews at hospital systems were stalling even the free deployments.
The bottleneck wasn’t the AI.
It was the frame buyers used to price it.
Initial internal assumptions priced the product against “AI software” benchmarks. Hospital executives weren’t evaluating it as software. They were evaluating it against recovered revenue.
A single successful appeal recovers approximately $21,000 in inpatient denial value. A major academic medical center processes 80,000+ discharges a year, generates 700+ denials a month, and overturns roughly 40% of what it fights. At that cadence, the ROI math is not a subscription decision. It is a revenue-recovery decision. The pricing frame had to match.
Hospitals weren’t wasting money on slow letter-writing. They were wasting physician time on appeals that were never going to be overturned. That reframe became the product’s commercial center of gravity.
From zero commercial strategy to a funded, sequenced launch plan in under 90 days.
1. Market sizing grounded in primary research, not analyst reports.
- Bottom-up TAM built from denial volume, denial value, overturn rates, and physician time displacement
- $2.8B core TAM, $1B SAM after filtering for customer penetration and technical readiness
- Cross-validated through three independent methods: top-down, bottoms-up unit economics, and comparable transaction analysis
2. Pricing architecture that made the buyer’s math obvious.
- Structured willingness-to-pay interviews with Directors of Clinical Appeals, Utilization Management, and Coding across multiple health systems
- Tiered pricing anchored to a 4:1 ROI floor, with 5:1 to 10:1 observed in pilot data
- 6-to-9-month payback, aligned to hospital budget cycles
- Front-loaded discount curve: 65-85% in Year 1 stepping down to 15-25% by Year 3
- Separate pricing architecture for existing-customer expansion versus net-new hospital systems, a segment the company had no framework for
3. Value proposition rebuilt around the metric that moves CFOs.
- Repositioned from “AI that writes appeal letters” to “AI that tells you which denials are worth fighting, then fights them”
- Appealability scoring became the core differentiator, not letter generation speed
- Reframe converted the company’s CMO from skeptic to internal champion after a single executive session
4. Launch sequence that attacked the real go-to-market blocker.
- Prioritized two hospital sites with existing Business Associate Agreements, bypassing six-month AI governance reviews entirely
- Introduced the company’s first try-before-you-buy pilot structure with defined conversion triggers
- Reframed the real bottleneck from engineering acceleration to legal and compliance enablement, removing months from the sales cycle
A five-year model the board could defend.
The financial model accounts for front-loaded discounts, $115K-$250K implementation revenue per client, and a disciplined view of cannibalization against existing $850K-$1.2M guideline subscriptions, a real risk given 68% prospect overlap with current customers.
| Year | Projected ARR | Customers | EBITDA margin |
|---|---|---|---|
| 1 | $8M | 85 | -60% |
| 2 | $22M | 175 | -18% |
| 3 | $42M | 300 | +6% |
| 4 | $65M | 425 | +15% |
| 5 | $90M | 550 | +22% |
What changed in 90 days.
- Validated pricing model that unlocked approximately 30x more revenue per customer than the company’s original assumptions
- Five-year financial model projecting $90M ARR with a clear path to EBITDA profitability by Year 3
- Repositioned value proposition (appealability scoring) that converted internal skeptics and resonated with hospital buyers
- Launch sequence that compressed time-to-first-revenue by routing through existing BAA sites first
- $25-40M in cannibalization risk identified with a mitigation strategy the finance team could own
- The company’s first try-before-you-buy pilot structure, designed to convert free users to paid contracts
The core insight: the product was never the bottleneck. The go-to-market was.
Sitting on a commercial unlock you can’t quite see?
Bring us the stuck revenue question. We’ll bring two operators, a point of view, and the commercial architecture your CFO can defend.
Start a conversation